Galantamine: use in Alzheimer’s disease and related disorders

References

• Howes MJ, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem. &hay 75(3), 513–271 (2003).
   Google Scholar
• Bosanquet N. Alzheimer's disease in the United Kingdom. Health Policy Unit, Imperial School of Medicine, London, UK (1998).
   Google Scholar
• Mace NL, Rabins PV. The 36-hour Day: a Family Guide to Caring for Persons with Alzheimels Disease, Related Dementing illnesses and Memory Loss in Later Life. Johns Hopkins University Press, BA, USA (1991).
   Google Scholar
• Först1 H, Kurz A. Clinical features of Alzheimer's disease. Eur. Arch Psych. Clin. Neurosci. 249,288-290 (1999).
   Google Scholar
• Barclay LL, Zemcov A, Blass JP, Sansone J. Survival in Alzheimer's disease and vascular dementia. Neurology 35,834–840 (1985).
   PubMed Web of Science ®Google Scholar
• Gauthier S. Phatmacotherapy of Alzheimels Disease. M Dunitz (Ed.). Martin Dunitz Ltd., London, UK (1998).
   Google Scholar
• Mohs RC, Schmeidler J, Aryan M. Longitudinal studies in cognition, functional and behavioural change in patients with Alzheimer's disease. Stars Med. 19,1401–1409 (2000).
   Google Scholar
• Cummings JL, Kaufer DI. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 47,876–883 (1996).
   PubMed Web of Science ®Google Scholar
• Melzer D, Ely M, Brayne C. Cognitive impairment in elderly people: population-based estimate of future in England, Scotland and Wales. BE Med. 1. 315,462 (1997).
   Web of Science ®Google Scholar
• Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408–414 (1982).
   PubMed Web of Science ®Google Scholar
• Traykova M, Traykov T, Hadjimitova V, Krikorian K, Bojadgieva N. Antioxidant properties of galantamine hydrobromide. Z Naturforsch. 58(5-6), 361–365 (2003).
   Google Scholar
• Greenblatt HM, Kryger G, Lewis T et al Structure of Acetykholinesterase complexed with H galantamine at 2.3 A resolution. FEBS Lett. 463,321-326 (1999).
   Google Scholar
• Bickel U, Thomsen T, Fischer JP et al Galantamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30, 447–454 (1991).
   PubMed Web of Science ®Google Scholar
• Thomsen T, Kaden B, Fischer JP et al Inhibition of acteylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine. Eur. j Clin. Chem. Clin. Biochem. 29, 487–492 (1991).
   PubMedGoogle Scholar
• Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol 6,75–111 (2000).
   Web of Science ®Google Scholar
• Perry E, Morris CM, Court JA et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease: possible index of early neuropathology. Neumscience 64, 385–395 (1995).
   PubMed Web of Science ®Google Scholar
• Nordberg A, Adem A, Hardy J, Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci. Lett. 86, 317–321 (1988).
   PubMed Web of Science ®Google Scholar
• Banerjee C, Nyengaard JR, Wevers A et al Cellular expression of a7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease — a stereological approach. Neurobiol Dis. 7,666–672 (2000).
   PubMed Web of Science ®Google Scholar
• Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology10, 93–107 (1994).
   PubMed Web of Science ®Google Scholar
• Sahakian BJ, Jones GMM. The effects of nicotine on attention, information processing and working memory in patients with dementia of the Alzheimer type. In: Effects of Nicotine on Biological Systems. Adlkofer F, Thruau K (Eds). Birkhauser Verlag, Basel, Switzerland (1991).
   Google Scholar
• Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer's disease. Drug- Disc.Today1,53–59 (1996).
   Web of Science ®Google Scholar
• Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement. Geriatr Cogn. Disord 11 (Suppl. 1), 11–18 (2000). Summarizes the important role of the nicotinic receptor as a target for treatment in Alzheimer's diesease (AD).
   Google Scholar
• Maelicke A, Samochocki M, Jostock R et al Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry 49, 279–288 (2001).
   PubMed Web of Science ®Google Scholar
• Woodruff-Pak DS, Vogel RVV III, Wenk GL. Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase and nicotinic acetylcholine receptors. Neuroscience 117(2), 439–447 (2003).
   PubMed Web of Science ®Google Scholar
• Schrattenholtz A, Pereira EFR, Roth U et al Agonist responses on neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mal Pharmacol 49(1), 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Schrattenholz A, Godovac-Zimmerman J, Schafer H-J et al Photoaffinity labelling of Torpedo acetylcholine receptors by physostigmine. Eur j Biochem. 216, 671–677 (1993).
   PubMedGoogle Scholar
• Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. Proc. Natl Acad. Sci. USA 99(19), 12432–12437 (2002).
   Google Scholar
• Arroyo G, Aldea M, Fuentealba J, Garcia AG. Nicotinic receptor, galantamine and Alzheimer's disease. Rev. Neural 34(11), 1057–1065 (2002).
   PubMed Web of Science ®Google Scholar
• Arias E, Ales E, Gabilan NH et al Galantamine prevents apoptosis induced by P-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46(1), 103–114 (2004). Links galantamine with neuroprotection in the laboratory and encourages the design of a proper disease modification study in man.
   Google Scholar
• Bickel U, Thomsen T, Weber W et al Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition. Clin. Pharmacol Ther. 50, 420–428 (1991).
   PubMed Web of Science ®Google Scholar
• Wood DM, Ford JM, Willcock GK et al Plasma protein binding of galantamine: a potential agent for the treatment of Alzheimer's disease. Eur. j Clin. Phalmacol 52(Suppl), A161 (1997).
   Google Scholar
• Mihailova D, Yamboliev I. Pharmacokinetics of galantamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. Phalmacology32, 301–306 (1986).
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica. Reminyl (galantamine) tablets prescribing information 11 July 2000. Janssen Pharmaceutica, NV, USA (2000).
   Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan Won behalf of the Galantamine USA-1 Study Group: Galantamine in AD — a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 54,2261–2268 (2000).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. Neurology54, 2269–2276 (2000).
   PubMed Web of Science ®Google Scholar
• Rogers S, Friedhoff L. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8(1), 67–75 (1998).
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J et al The effects of donepezil in Alzheimer's disease — results from a multinational trial. Dement. Ceriatr Cogn. Disord. 10,237–244 (1999).
   PubMed Web of Science ®Google Scholar
• Robillard A, McKelvey R, Nasreddine Z. Galantamine improves quality of sleep in patients previously treated with donepezil (preliminary results). Presented at the 14th Annual Meeting of the American Association for Geriatric Bychiatry San Francisco CA, USA, February 23–26 (2001).
   Google Scholar
• Mintzer J, Kershaw P The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. int. Ceriatr Psych. 18(4), 292–297 (2003).
   PubMed Web of Science ®Google Scholar
• Rasmusen L, Yan B, Robillard A, Dunbar E Effects of washout and dose-escalation periods on the efficacy, safety and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin. Ther. 23(Suppl. A), A25—A30 (2001).
   Google Scholar
• Wilkinson D, Murray JR. Galantamine: a randomised, double-blind, dose-finding trial in patients with Alzheimer's disease. Int.j Ceriatr Psych. 16(9), 852–857 (2001).
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens Eon behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: a multicentre randomised controlled trial. BE Med. 321,1445-1449 (2000).
   Google Scholar
• Rockwood K, Mintzer J, Truyen L. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. j Neural Neurosurg. fiychiatry71, 589–595 (2001).
   Google Scholar
• Mintzer J, Kershaw P Galantamine provides cognitive and functional benefits over 12 months in patients with Alzheimer's disease. Presented at the 125th Annual Meeting of the American Neurological Assodation, Boston, MA, USA. 15–18 October (2000).
   Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am. Psych. 141,1356–1364 (1984).
   Google Scholar
• Schneider LS, Olin JT, Doody RS et al Validity and reliability of the Alzheimer's disease Co-operative Study — Clinical Global Impression of Change, The Alzheimer's disease Co-operative Study. Alzheimer Dis. Assoc. Disonl 11 (Suppl. 2), S22—S32 (1997).
   Google Scholar
• Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K. Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. Dement. Ceriatr Cogn. Disord 15(1), 26–33 (2003).
   Google Scholar
• Galasko D, Bennett D, Sano M et al An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease Co-operative Study. Alzheimer Dis. Assoc. Disonl 11 (Suppl. 2), S33—S39 (1997).
   Google Scholar
• Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.Am.j Occup. Ther. 53,471–481 (1999).
   PubMed Web of Science ®Google Scholar
• Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48\(Suppl. 6), S10—S16 (1997).
   Google Scholar
• Huang F, Lasseter KC, Janssens L, Verhaeghe T, Lau H, Zhao Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. Clin. Phalmacol 42(12),1341–1351 (2002).
   Google Scholar
• Blesa R. Galantamine: therapeutic effects beyond cognition. Dement. Ceriatt: Cogn. Disord 11 (Suppl. 1), 28–34 (2000).
   Google Scholar
• Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin. Pharmacol Ther. 58,228–236 (1995).
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Kershaw P Galantamine produces cognitive, functional and global benefits in patients with Alzheimer's disease: pooled data from two 6-month studies. Presented at the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy Stockholm, Sweden, April (2000).
   Google Scholar
• Lilienfeld S, Parys W Galantamine: additional benefits to patients with Alzheimer's disease. Dement. Ceriatr Cogn. Disord 11 (Suppl. 1), 19–27 (2000).
   Google Scholar
• Blesa R, Davidson M, Kurz A, Reichman W van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement. Ceriatr Cogn. Disord 15(2), 79–87 (2003).
   Google Scholar
• Farlow MR, Lahiri DK, Poirier J et al Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. NY Acad. Sci. 802,101–110 (1996).
   PubMed Web of Science ®Google Scholar
• Stem RG, Mobs RC, Dividson M et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am. J. Psychiatry 151,390–396 (1994).
   PubMed Web of Science ®Google Scholar
• Raskind M, Truyen L. The cognitive and functional benefits of galantamine; a 12-month study in Alzheimer's disease. Presented at the 125th Annual Meeting- of the American Neurological Association. Boston, MA, USA, October 15–18 (2000).
   Google Scholar
• Tariot P, Winblad B. Galantamine, a novel treatment for Alzheimer's disease: a review of long-term benefits to patients and caregivers. In: Alzheimer Disease: Advances in Etiology Pathogenesis and Therapeutics. Iqbal K, Sisodia SS, Winblad B (Eds). John Wiley & Sons Ltd, NJ, USA, 707–723 (2001).
   Google Scholar
• Torfs K, Feldman H. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: two randomized placebo-controlled studies. Presented at the World Alzheimer Congress (WAG). Washington DC, USA, July (2000).
   Google Scholar
• Winblad B. Maintaining functional and behavioral abilities in Alzheimer's disease. Alzheimer Dis. Assoc. Disord 15 (Suppl. 1), S34—S40 (2001).
   Google Scholar
• Lilienfeld S, Gaens E. Galantamine alleviates caregiver burden in Alzheimer's disease: a 12-month study. Presented at the 5th Congmss of the European Federation of Neurological Societies IEENS1. Copenhagen, Denmark, October 14–18 (2000).
   Google Scholar
• Wilcock GW, Truyen L, Lilienfeld S, Mahableshwarkar AR. Long-term cognitive effects of galantamine in the treatment of mild-to-moderate Alzheimer's disease: evidence from 48 months of treatment. Presented at the American Psychiatric Association 156th Annual Meeting. San Francisco, CA, USA, May 17–22 (2003).
   Google Scholar
• Soininen H, Martin S, Bullock R et al. First head-to-head study comparing the efficacy of donepezil and galantamine in Alzheimer's disease. 15th Congress of the European College of Neuropsychopharmacology. Barcelona, Spain, October (2002).
   Google Scholar
• Wilcock G, Howe I, Coles H et al, and members of the GAL-GBR-2 Study Group. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging20, 777–789 (2003).
   Google Scholar
• ••The first long-term comparison study oftwo acetylcholinesterase inhibitors, one with and one without nicotinic modulation, which produced cognitive results to show the nicotinic effect is measurable in man.
   Google Scholar
• Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TVV Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J. Neurosci. 20(3), 1208–1215 (2000).
   Google Scholar
• Erkinjuntti T, Kurz A, Gauthier S et al Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359,1283-1290 (2002). The first published data showing the positive effect of a cholinesterase inhibitor in cerebrovascular disease.
   Google Scholar
• Erkinjuntti T, Kurz A, Small G W Bullock R, Lilienfeld S, Damarju CV, for the GAL-INT-6 Study Group. Open-label extension trial of galantamine probable vascular dementia and mixed dementia. Clin. Ther. 25,1765-1782 (2003).
   Google Scholar
• Kurz A, Erkinjuntti T, Bullock R et al Long-term safety and efficacy of galantamine in the treatment of probable vascular dementia and Alzheimer's disease with cerebrovascular disease: an interim analysis. Presented at the 16th Annual meeting of the American Association of Geriatric Psychiatry Hawaii, USA, March (2003).
   Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Use of galantamine to treat vascular dementia. Lancet 360(9344), 1512–1513 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu L, Fratiglioni L, Guo Z et al. Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project. Neurology54(11), 2103–2107 (2000).
   PubMed Web of Science ®Google Scholar
• Wild R, Pettit T, Bums A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Sys. Rev. (3), CD003672 (2003).
   Google Scholar
• Edwards K, Hershey 1, Lichter D et al Galantamine in the management of dementia with Lewy bodies. Presented at the American Bychiatric Association 156th Annual Meeting; San Francisco, CA, USA, May 17–22 (2003).
   Google Scholar
• Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien J. Clinical predictors of response to acetylcholinesterase inhibitors, experience from routine use in Newcastle. Int. J. Ger. Psychiaby18, 879–886 (2003).
   PubMed Web of Science ®Google Scholar
• Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin. Neuropharmacol 25(5), 272–275 (2002).
   PubMed Web of Science ®Google Scholar
• Allen T, McAvoy JP, Keefe R et al Galantamine improves cognition in patients with schizophrenia. Presented at the American Psychiatric Association 156th Annual Meeting; San Francisco, CA, USA, May 17–22 (2003).
   Google Scholar
• Niederhofer H, Staffen W Mair A. Galantamine may be effective in treating autistic disorder. BE Med. J. 325(7377)1422 (2002).
   Google Scholar
• Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am. J. Public Health 77,1169–1175 (1987).
   PubMed Web of Science ®Google Scholar
• Hux MJ, O'Brien BJ, Iskediian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CM4J159, 457–469 (1998).
   Google Scholar
• Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis. Assoc. Disoml. 13, S9—S19 (1999).
   Web of Science ®Google Scholar
• Caro JJ, Getsios D, Migliaccio-Walle D et al Assessment of health economics in Alzheimer's disease (AHEAD) based on the need for full time care. Neurology 57, 964–971 (2001). A robust economic model that shows how galantamine can positively affect the cost of treatment in AD.
   Google Scholar
• Ward A, Caro JJ, Getsios D, Ishak K, 0' Brien J, Bullock RA for the AHEAD Study Group. Assessment of Health Economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. hit.j Ger. Fiych. 18,740-747 (2003).
   Google Scholar
• Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. hit.j Clin. Prac. 127,64–72 (2002).
   Google Scholar
• Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst. Rev. (3), CD001747 (2003).
   Google Scholar
• ••A full Cochrane review that supports the efficacy of galantarnine when scrutinized using strict evidence-based criteria.
   Google Scholar
• Wenk GL, Quack G, Moebius HJ, Danysz W No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 66(12), 1079–1083 (2000).
   Google Scholar